Search these posts for articles, publications, research studies & discussions relevant to Phoenix Technology Group products.

Research Blog

2020

A year-long longitudinal pattern dystrophy fundus study with the Phoenix MICRON™ IV imaging platform

In their 2019 paper, “Novel molecular mechanisms for Prph2‐associated pattern dystrophy,” Chakraborty et al use the Phoenix MICRON™ IV retinal imaging platform to longitudinally study the effect of a very specific mutation affecting the Peripherin 2 protein. Peripherin 2 is a protein in rods and cones which, if mutated, can lead to retinitis pigmentosa, cone-rod

2020

RPE mutations lead to retinal hypopigmentation, vasculature changes, and decreased function

In their paper, “The microphthalmia-associated transcription factor (Mitf) gene and its role in regulating eye function,” García-Llorca et al use the Phoenix MICRON™ IV to examine the outer eye appearance, retinal pigmentation, and retinal vasculature through fluorescein angiography to study several different mouse mutants. Combined with electroretinography and histology, the fundus images tell a story

2020

Phoenix MICRON™ III shows microglia-like cells migrating from the optic nerve after injury

Microglia respond to neurological injury but the precise way they help to clear and remodel the injuries is not known. In their paper, “Optic nerve as a source of activated retinal microglia post-injury,” Heuss et al investigate a population of microglia-like cells that proliferate in the retina after an optic nerve injury. They identify GFPhi myeloid

2020

Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON™, OCT, and focal ERG

In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.

2020

Targeting VEGF164 in Müller cells may be useful to treat retinopathy of prematurity

In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by

2020

Imaging unanesthetized mice with the Phoenix MICRON™ OCT provides consistent retinal degeneration measurements

In the recently published review, “Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss,” researchers from The Jackson Laboratory in Bar Harbor, Maine and Mahidol University in Bangkok, Thailand performed an extensive literature search to find mouse models of single-gene mutations leading to photoreceptor loss and retinal degeneration. Using the Phoenix MICRON III and

1 2 3 6